Research and Presentations – John Paul Runyon


The following are research and presentations of Dr. John Paul Runyon:

CLINICAL RESEARCH TRIALS: DEVICES

Co-Investigator
iDEV Technologies, Inc.
Comparison of the SUPERA® Peripheral System to a performance goal derived from Balloon Angioplasty Clinical Trials in the Superficial Femoral Artery. (The SUPERB Study). Protocol No. SFA- 1-US/EU.

Principal Investigator
Cardiva Medical Inc.
BOOMERANG Trial II: Protocol No. 2006-100 BoomerangTM ClosureWire Vascular Access Management System.D

Principal Investigator
Fox Hollow Technologies
LEAP (Phase Zero): A two-part, multicenter, randomized, double-blind, placebo-controlled study to evaluate the effect of Simvastatin, Losartan, and Pioglitazone on cardiovascular disease biomarkers in lower extremity atherosclerotic plaque excised from patients with peripheral arterial disease.

Principal Investigator
Abbott Vascular Devices
ACT I: Carotid angioplasty and stenting versus carotid endarterectomy in asymptomatic subjects who are at risk for carotid endarterectomy with significant extra-cranial carotid occlusive disease. A prospective, randomized, parallel, two-arm, multi-center trial. 3:1 ratio of CAS versus CEA.

Principal Investigator
Guidant Corporation
CAPTURE Trial: The Carotid Stent and Embolic Protections System.

Principal Investigator
Edwards LifeSciences, LLC
RESILIENT Trial: A randomized study comparing the Edwards self-expanding LifeStent vs. angioplasty- alone in lesions involving the SFA and/or proximal popliteal artery.

Co-Investigator
FoxHollow Technologies
TALON: A prospective, multicenter, observational outcomes database registry designed to collect data on the demographics, plaque excision procedures and follow-up results for patients with peripheral arterial disease.

Co-Investigator
Vascular Architects, Inc.
ASPIRE: Valiant, Vascular Architects Femoralpopliteal Sub-Optimal Angioplasty Aspire Trial.

Principal Investigator
NightHawk
A Non-Randomized study of the NightHawk Peripheral Plaque Excision System during plaque excision of peripheral arterial disease.

Principal Investigator
EASE: A prospective multicenter evaluation of the safety and effectiveness of the Phoenix AtherectomyTM System in atherectomy of the peripheral vasculature.

Principal Investigator
DEFINITIVECa++:DeterminationofthesafetyandeffectivenessoftheSilverHawkTM PeripheralPlaque Excision system for Calcium (SilverHawk LS-C) and the SpiderFXTM Ebolitic Protection Device for the treatment of calcified peripheral aterial disease in the superficial femoral and/or the popliteal arteries.

Principal Investigator
DEFINITIVE LE: Determination of effectiveness of SilverHawk Peripheral Plaque Excision (SilverHawk Device) for the treatment of infrainguinal vessels/lower extremities.

Principal Investigator
GORE VIABAHN Endoprosthesis Versus Bare Nitinol Stent in the Treatment of Long Occlusive Disease.

Co-Investigator
Second phase of carotid RX ACCULINK/RX ACCUNET post-approval trial to uncover unanticipated rare events.

Principal Investigator
AtheroMed Inc.
EASE: Prospective, multicenter clinical evaluation of the safety and effectiveness of the Phoenix AtherectomyTM System in Atherectomy of the Peripheral Vasculature.

Principal Investigator
C.R. Bard
Crosser Enters the Right Arterial Lumen (CENTRAL)

Principal Investigator
Atrium Medical Corporation
Atrium iCAST Iliac Stent Pivotal Study (ICARUS)

Co-Investigator
Boston Scientific
Boston Scientific Embolic Protection Inc. (EPI): A carotid stenting trial for high-risk surgical patients (BEACH

Principal Investigator
CABERNET: Carotid artery revascularization in high-surgical-risk patients with the NexStent and the FilterWire EX/EZ.

Co-Investigator
Gore EMPIRE clinical study to evaluate safety and efficacy of the GORE® Flow Reversal System for neuroprotection during carotid artery stenting.

Principal Investigator
Abbott Vascular
CHOICE: Carotid Stenting for High-Risk Surgical Patients.

Principal Investigator
FoxHollow
TALON Registry: Treating peripherals with SilverHawk.

Co-Investigator
Gore
GORE® Embolic Filter in carotid stenting for high-risk surgical subjects (GORE EMBOLDEN)

Principal Investigator
Boston Scientific
ORION: A Boston Scientific trial of the Epic Self-Expanding Nitinol stent in the treatment of atherosclerotic lesions in iliac arteries.

Principal Investigator
Medtronic
PIVOTAL: A randomized comparison of endovascular repair versus surveillance in patients with smaller abdominal aortic aneurysms.

Co-Investigator
National Institute of Neurological Disorders (NINDS) National Institutes of Health (NIH)
CREST: Carotid revascularization endarterectomy vs. stenting.

Co-Investigator
Abbott Vascular
ACT-1: A randomized trial to demonstrate the non-inferiority of carotid artery stenting (CAS), using the Emboshield® Embolic Protection System with the Xact® Carotid Stent System, to carotid endarterectomy (CEA) for the treatment of asymptomatic extracranial carotid atherosclerotic disease in subjects considered at standard risk for adverse events from CEA.

Co-Investigator
IntraLuminal Therapeutics, Inc
GRIP: Guided radio frequency in peripheral total occlusions, a 50-patient, multicenter, non-randomized registry.

Principal Investigator
FoxHollow
TALON: A prospective, multi-center, observational outcomes database registry.

Principal Investigator
FoxHollow
RED-TAIL: Registry of SFA bilateral diseases treated with the SilverHawk System. (Multi-center, prospective, outcomes database registry.)

Principal Investigator
FoxHollow
MERLIN: Multiple lesions from a unilateral extremity treated with SilverHawk in a single procedure. (Multi-center, prospective, outcomes database registry.)

Co-Investigator
Abbott Vascular Devices
EXACT: Emboshield and Xact post-approval carotid stent trial. (Multi-center, observational, single-arm, post-approval study).

Principal Investigator
FoxHollow
LEAP: A two-part, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of Simvastatin, Losartan, and Pioglizatone on cardiovascular disease biomarkers in lower extremity atherosclerotic plaque excised from patients with peripheral arterial disease.

Principal Investigator
FoxHollow
SWIFT: Femoropopliteal Disease treated with the SilverHawk Plaque Excision System: A non- randomized registry with duplex ultrasound follow-up at twelve months.

Principal Investigator
FlowMedica
PATRICIA: A Multi-Center, Randomized, Open Label Trial of Intra-renal Fenoldopam Mesylate vs. Intravenous Sodium Bicarbonate and Oral N-acetylcysteine in Patients at High Risk for Contrast Induced Neuropathy Undergoing Peripheral Vascular Intervention.

Principal Investigator
FoxHollow
BROADWING: Biological Waste MateRial and Outcomes analysis of Lower Extremity Peripheral Disease Treated with the SilverHawkTM Plaque ExcisioN System: A Tissue and Data ReGistry.

Principal Investigator
FoxHollow Technologies, Inc.
NIGHTHAWK: Evaluation of the NightHawk peripheral excision system for patients with infrainguinal lesions. (20-patient, non-randomized, multi-center trial).

Principal Investigator
EV3
DEFINITIVE CA++: SilverHawk LS-C with SpiderFX in lower extremity PAD undergoing plaque excision (102-patient, prospective, multi-center, non-randomized, single-arm study).

Principal Investigator
Idev Technologies, Inc.
SUPERB-SUPERA: Nitinol Stent System in treating subjects with obstructive SFA disease. (258-patient prospective, multi-center, non-randomized, single-arm trial).

Co-Investigator
Abbott Vascular
CHOICE: Carotid Stenting for High-Risk Patients: Evaluating Outcomes Through Collection of Clinical Evidence. (Open-ended enrollment, non-randomized, multi-center trial).

Co-Investigator
Abbott Vascular
ACT I: Carotid Angioplasty and stenting versus endarterectomy in asymptomatic subjects with significant extracranial carotid occlusive diseases (1,540-patient, multi-center, randomized trial).

Co-Investigator
Lutonix Inc.
LEVANT 2: MoxyTM drug-coated balloon vs. standard balloon angioplasty for treatment of femoropopliteal arteries (500-patient, prospective, multi-center, single-blind, randomized trial).

Co-Investigator
ANTRIN: Photoangioplasty for human peripheral atherosclerosis, a Phase 1 trial of photodynamic therapy with motexafin lutetium (Antrin).

Principal Investigator
MOBILE: A randomized study for the treatment of in-stent restenosis in SFA lesions using the Corona system.

Principal Investigator
CSI
OASIS: A prospective, non-randomized, multi-center trial to assess the safety and short-term efficacy of orbital atherectomy for chronic infrapopliteal arterial occlusive disease.

Principal Investigator
IDev Technologies
SUPERB: Comparison of the SUpera® PERipheral System to a performance goal derived from balloon angioplasty clinical trials in the superficial femoral artery.

Principal Investigator
NIH
CORAL: Cardiovascular Outcomes in Renal Atherosclerotic Lesions. A study to compare medical therapy plus stenting of hemodynamically significant renal artery stenosis versus medical therapy alone in patients with systolic hypertension and renal artery stenosis.

Co-Investigator
Abraxis BioScience Inc.
ABRAXANE: Phase II, randomized, open-label, prospective, multicenter study trial to evaluate the efficacy and safety of three different dosing schedules of CoroxaneTM for the prevention and reduction of restenosis following revascularization of the superficial femoral artery (SFA).

Sub-Investigator
Global Therapeutics
Magellan coronary dilation catheter.

Co-Investigator
NIR VASCULAR ADVANCED NORTH AMERICAN TRIAL (NIRVANA TRIAL) (NIR STENT) .

Sub-Investigator
EXTRA: Evaluation of the XT Stent for Restenosis in Native Arteries.

Co-Investigator
Randomized trial of localized radiation therapy to inhibit restenosis after stenting.

Sub-Investigator
ACS Multi-Link Duet Coronary Stent system in treatment of patients with de novo native coronary artery lesions.

Sub-Investigator
Angiorad Radiation for RESTenosis Unstented Native Vessels (ARREST).

Sub-Investigator
Palmaz-Schatz Mini Crown balloon expandable stent mounted on the Cordis Dynasty OTW delivery system for pts undergoing elective MiniCrown stent placement vs. angioplasty in small coronary arteries (MICA).

Sub-Investigator
Angiorad radiation therapy for in-stent restenosis intra coronaries (ARTISTIC).

Sub-Investigator
Non-randomized, prospective, multicenter, consecutive registry of native coronary artery and arterial bypass graft conduits with the AVE GFX 2.5 stent for acute or threatened closure indication.

Sub-Investigator
Guidant intravascular radiotherapy system in the treatment of in-stent restenosis.

Sub-Investigator
DISTINCT Trial: Biocompatibles Stent.

Sub-Investigator
GAMMA II: Multicenter trial of localized radiation therapy to inhibition restenosis after stenting.

Sub-Investigator
ACS Multi Link ULTRA coronary stent system in pts with SVG and native coronary artery lesions.

Sub-Investigator
PREDICT Trial for S670 coronary stent system: Predilitation vs. direct stenting in coronary treatment.

Sub-Investigator
GAMMA IV: Continued access trial of localized radiation therapy to inhibit restenosis after stenting.

Sub-Investigator
SLIDE Registry: Select lesion indication for direct stenting: Registry to evaluate the ACS MULTI-LINK Tristar stent system in treatment of patients with de novo and restenotic native coronary artery lesions using a no pre-dilatation implantation strategy.

Sub-Investigator
High Scaffolding SVG Registry (Medtronic AVE).

Sub-Investigator
Antrin injection & far red light activation in pts. with CAD undergoing PCI with stent placement (Antrin/PTCA).

Sub-Investigator
X-TRACT: X-Sizer for Treatment of Thrombus & Atherosclerosis in Coronary Interventions Trial.

Sub-Investigator
CONSERVE: Comparison of new stents for equivalency of reduction in vascular events.

Sub-Investigator
A non-randomized evaluation of the multi-link rx tetra coronary stent system in the tx. of pts. with de novo native coronary artery lesions.

Sub-Investigator
Biocompatibles BiodivYsioTM stent non-randomized control trial (DISTINCT Stent Sizes Registry).

Sub-Investigator
QUICKSEAL delivery system for achieving hemostasis of the arterial access site as compared to manual compression.

Sub-Investigator
GAMMA V: A multicenter trial of localized radiation therapy to inhibit restenosis.

Sub-Investigator
TENAX XR Registry (coronary stent study).

Sub-Investigator
SWING: Sound Wave Inhibition of Neointimal Growth.

Sub-Investigator
ARTISTIC II: AngioRad radiation therapy for in-stent restenosis intracoronaries.

Sub-Investigator
TRAP Vascular Filtration System Trial.

Sub-Investigator
A non-randomized evaluation of the MULTI-LINK RX PENTA coronary stent system in the rx. of pts. with de novo native coronary artery lesions.

Sub-Investigator
SIRIUS Study: A multicenter, randomized, double blind study of the Sirolimus-Coated Bx VELOCITY balloon-expandable stent in the tx. of pts. with de novo coronary artery lesions.

Sub-Investigator
BRITE II Trial: The Beta Radiation to Reduce In-Stent Restenosis II Trial.

Sub-Investigator
VICTORY: Elective & acute stenting of coronary arteries on Express System.

Sub-Investigator
MULTI-LINK VISION Registry: A non-randomized evaluation of the MULTI-LINK VISION Coronary Stent System in the Tx. of Pts. with de novo Native Coronary Artery Lesions.

Sub-Investigator
JOSTENT SVG BARRICADE Trial: The Barrier Approach to Restenosis: Restrict Intima & Curtail Adverse Events).

Sub-Investigator
Repeat intracoronary radiation for patients who failed radiation therapy: a compassionate use protocol.

Sub-Investigator
DELIVER: Prospective, Randomized…. evaluation of the Rx Achieve drug-coated coronary stent system in the tx. of pts. with de novo native coronary artery lesions.

Sub-Investigator
Filter Wire During Transluminal Intervention of Saphenous Vein Grafts (FIRE).

Sub-Investigator
TAXUS IV: A prospective, randomized…TAXUS Paclitaxel-eluting coronary stent in de novo coronary lesions & in-stent restenosis.

Sub-Investigator
Medtronic AVE S8 Coronary Stent System in denovo and restenotic lesions

Sub-Investigator
NIRFLEX stent study.

Sub-Investigator
ULTIMA: Multicenter, prospective study of the Sirolimus-eluting BX velocity balloon-expandable stent in the treatment of patients with unprotected left main coronary artery lesions.

Sub-Investigator
PREFER Trial: Prospective study to evaluate the safety and efficacy of two doses of ABT-578 coated BiodivYsio Stent for the Reduction of Restenosis.

Sub-Investigator
JOSTENT registry: for coronary artery perforations, coronary artery aneurysms and pseudoaneurysms and arteriovenous fistulas.

Sub-Investigator
Clinical evaluation of the Medtronic AVE Interceptor embolic protection device during PI on SVGs..

Sub-Investigator
TAXUS V: A randomized….trial to assess TAXUS Paclitaxel-eluting coronary stents, slow release formulation in the treatment of high risk de novo coronary lesions.

Principal Investigator
Medtronic AVE Micro-Drive Registry.

Sub-Investigator
The SLK-ViewTM Side-Access Coronary Stent Non-Randomized Pivotal Study.

Sub-Investigator
PROXIMAL protecting during saphenous vein graft intervention using the Proxis embolic protection system: a randomized, prospective multicenter, clinical trial.

Sub-Investigator
TAXUS V ISR: A prospective, randomized trial evaluating the slow-release formulation TAXUS paclitaxel-eluting coronary stent in the treatment of in-stent restenosis.

Sub-Investigator
Feasibility study of inducing mild hypothermia in acute MI using non-invasive cooling with Medivance® Artic SunTM system.

Sub-Investigator
SIRIUS: 2.25 mm: A multicenter, non-randomized study of the 2.25 mm Sirolimus-eluting BX Velocity balloon expandable stent in the treatment of patients with de novo native coronary artery lesions.

Sub-Investigator
SIRIUS: 4.0 mm: A multicenter, non-randomized study of the 4.0 mm Sirolimus-eluting BX Velocity balloon expandable stent in the treatment of patients with de novo native coronary artery lesions.

Sub-Investigator
ENDEAVOR III: A randomized controlled trial of the Medtronic Endeavor Drug (ABT-578) Eluting Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System in de novo native coronary artery lesions.

Sub-Investigator
RESILIENT Trial: A Randomized study comparing the Edwards Self-Expanding LifeStent vs. angioplasty alone in lesions involving the SFA & proximal popliteal artery.

Sub-Investigator
A multicenter, non-randomized study of the CypherTM NxT Sirolimus-eluting coronary stent on the BX SonicTM Over-The-Wire (OTW) Stent Delivery System (SDS) for the treatment of de novo native coronary artery lesions.

Sub-Investigator
Future IV Clinical Trial: A Clinical evaluation of the CHAMPIONTM Everolimus Eluting Coronary Stent (EECS) System in the treatment of patients with de novo native coronary artery lesions.

Sub-Investigator
ZoMaxx II Trial: A randomized controlled trial to evaluate the safety and efficacy of the ZoMaxxTM Drug Eluting Coronary Stent System in de novo coronary arterial lesions.

Sub-Investigator
SPIRIT III: A clinical evaluation of the XIENCE V Everolimus Eluting Coronary Stent (EECS) System in the treatment of subjects with de novo native coronary artery lesions.

Sub-Investigator
COSTAR Trial: CObalt chromium STent with Antiproliferative for Restenosis.

Sub-Investigator
ENDEAVOR IV: A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System versus the TaxusTm Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions.

Sub-Investigator
SPIRIT IV: XIENCE V Everolimus Eluting Coronary Stent System in the Tx. of Sub. with de novo Native Coronary Artery Lesion.

Sub-Investigator
TAXUS PERSEUS: A Prospective Evaluation in a Non-Randomized Trial of the Safety and Efficacy of the Use of the TAXUS® ElementTM Paclitaxel-Eluting Coronary Stent System for the treatment of de novo coronary artery lesions in small vessels.

Sub-Investigator
TAXUS PERSEUS: WORKHORSE: A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS® ElementTM Paclitaxel-Eluting Coronary Stent System for the treatment of de novo coronary artery lesions.

Sub-Investigator
RETRIEVE Study: Evaluating the use of the FiberNet Embolic Protection System in saphenous vein grafts.

Sub-Investigator
A prospective, single blind, randomized, multi-center, study comparing the CYPHER® ELITETM and the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems.

Sub-Investigator
CORAL: Cardiovascular Outcomes in Renal Atherosclerotic Lesions.

Sub-Investigator
PROTECT II: A prospective, multi-center, randomized controlled trial of the IMPELLA® RECOVER® LP 2.5 System versus Intra Aortic Balloon Pump (IABP) in patients undergoing non emergent high risk PCI.

Sub-Investigator
A clinical evaluation of the ABT Everolimus Eluting Coronary Stent System: SPIRIT Small Vessel/Long Lesion Clinical Trial

Co-Investigator
XIENCETM V Everolimus Eluting Coronary Stent System (EECSS) USA post-approval study.

Sub-Investigator
SPIRIT Small Vessel Registry (SPIRIT SV) Clinical Trial: A clinical evaluation of the 2.25mm XIENCE V Everolimus eluting coronary stent system.

Sub-Investigator
RESOLUTE: A clinical evaluation of the Medtronic Endeavor Resolute Zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries with a reference vessel diameter of 2.25mm to 4.2mm.

Sub-Investigator
SPIRIT Small Vessel Registry (SPIRIT SV) Clinical Trial: A clinical evaluation of the 2.25mm XIENCE V Everolimus Eluting Coronary Stent System.

Sub-Investigator
RESOLUTE: A clinical evaluation of the Medtronic Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in the treatment of de novo lesions in native coronary arteries with a reference vessel diameter of 2.25mm to 4.2mm.

Sub-Investigator
PLATINUM: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS ElementTM) for the Treatment of up to two De Novo Coronary Artery Lesions..

Sub-Investigator
SPIRIT PRIME Clinical Trial: A clinical evaluation of the XIENCE PRIMETM and XIENCE PRIMETM LL Everolimus Eluting Coronary Stent System.

Sub-Investigator
CYPRESS: P09-6301: A prospective, randomized, multi-center, double-blind trial to assess the effectiveness and safety of different durations of Dual Anti-Platelet Therapy (DAPT) in subjects undergoing percutaneous coronary intervention with the CYPHER® Sirolimus-eluting Coronary Stent (CYPHER® Stent).

Sub-Investigator
ROSS Clinical Study: A Clinical evaluation of the MINI TREK RX 1.20 mm Coronary Dilatation Catheter in Stenotic Lesions.

Sub-Investigator
OMEGA: A prospective, multicenter single-arm trial to assess the OMEGATM coronary stent system for the treatment of a single de novo coronary artery lesion.

CLINICAL RESEARCH TRIALS: PHARMACEUTICALS

Principal Investigator
MK0633: The Effect of MK 0633 in patients with atherosclerosis (0633-008).

Principal Investigator
APPROVE: The Angiomax Peripheral Procedure Registry of Vascular Events, a prospective, open-label, single-arm study in patients undergoing PPI of the renal, iliac, or femoral vessels to assess bivalirudin as the sole procedural anticoagulant.

Principal Investigator
Calypso Trial: A double-blind, placebo-controlled, multi-center study of Cylexin and prevention of myocardial perfusion injury in patients with acute myocardial infarction treated with primary angioplasty.

Principal Investigator
Gusto III: A randomized trial of Reteplase versus Alterplase for the treatment of acute myocardial infarction.

Principal Investigator
HITTS: An open-label study of Novastan in patients with Heparin-Induced Thrombocytopenia or Heparin- Induced Thrombocytopenia with Thrombosis Syndrome.

Principal Investigator
Prism: A randomized, parallel, double-blind study to investigate the safety and clinical efficacy of MK- 383 versus heparin in patients with unstable angina/non-Qwave myocardial infarction.

Principal Investigator
Pursuit: A randomized, double-blind evaluation of the efficacy and safety of two dosing regimens of Integrelin versus placebo for reducing mortality and myocardial re-infarction in patients with unstable angina or non-Qwave myocardial infarction.

Principal Investigator
Rapport: ReoPro in acute myocardial infarction and primary PTCA organization and randomized trial.

Principal Investigator
SHOCK (Should We Emergently Revascularize Occluded Coronaries For Cardiogenic Shock): An international randomized trial of emergency PTA/CABG.

Principal Investigator
STARS (Stent Anti-Thrombotic Regimen Study).

Principal Investigator
TIMI 10A: A phase 1, open-label, multi-center, dose-escalation, single-dose administration study to determine the pharmacokinetics, pharmacodynamics, safety, and tolerance TNK-t-PA in acute myocardial infarction.

Principal Investigator
TIMI 10B: A phase 2, randomized, ,open-label, multi-center, international, angiographic trial of the efficacy of TNK-t-PA compared with accelerated Activase in acute myocardial infarction.

Principal Investigator
TIMI 12: A phase 2, multi-center, randomized, double-blind, aspiring-controlled study to evaluate pharmacokinetic, pharmacodynamics, and safety of Ro48-3657 an oral platelet glycoprotein IB/IIIa antagonist in subjects post and acute coronary syndrome.

Sub-Investigator
Praise: Prospective randomized Amlodipine survival evaluation.

Sub-Investigator
Caprie: Clopidogrel vs. aspirin in patients at risk of ischemic events.

Sub-Investigator
Dilacor XR in angina.

Sub-Investigator
Fantofarone (SR 33557 in patients with chronic stable angina pectoris.

Sub-Investigator
Adenosine as an adjunct to tissue-type Plasminogen Activator (rt-PA) in the treatment of acute myocardial infarction.

Sub-Investigator
Atlas: Assessment of treatment with Lisinopril and survival.

Sub-Investigator
Open-label safety study of intravenous Amiodarone HCL in patients with life-threatening ventricular tachycardia/fibrillation.

Sub-Investigator
Safety and efficacy of Cardizem CD for the treatment of stable angina pectoris.

Sub-Investigator
Efficacy and safety evaluation of Verapamil-GITS 240 mg in the treatment of stable angina pectoris.

Sub-Investigator
CARS: Coumadin/Aspiration Reinfarction Study.

Sub-Investigator
Impact: A randomized, double-blind, comparative safety and efficacy evaluation of Integrilin in patients receiving thrombolytic therapy for acute myocardial infarction.

Sub-Investigator
SWORD (Survival with Oral d-Sotalol): The effect of oral d-Sotalol on mortality in patients with atherosclerotic coronary heart disease and left ventricular dysfunction.

Sub-Investigator
Open-label dose range study of multiple oral doses of NE-10064 to determine safety and anti-arrhythmic efficacy in patients with inductible monomorphic ventricular tachycardia by Programmed Electrical Stimulation (PES).

Sub-Investigator
Open-label, long-term safety of Ro 40-5967 in the treatment of chronic stable angina.

Sub-Investigator
AFIB: Atrial Fibrillation investigation with Bidisomide.

Sub-Investigator
A randomized study of MK-383 in high-risk patients undergoing PTCA.

Sub-Investigator
Gusto II: Global use of strategies to open occluded arteries in acute coronary syndromes.

Sub-Investigator
IMPACT II: Two dosing regimens of Integrilin versus placebo for reducing the complications of coronary angioplasty

Sub-Investigator
Comparison of Oral BMS 180291, Atenolol and placebo in subjects with coronary artery disease experiencing episodes of ambulatory myocardial ischemia.

Sub-Investigator
Comparison of the efficacy and safety of extended outpatient treatment with subcutaneous Normiflo versus placebo for the prevention of venous thromboembolism in patients after hip or knee replacement surgery.

Sub-Investigator
CORE: Collaborative Organization for RheothRx Evaluation.

Sub-Investigator
Antihypertensive activity and safety of 100, 200, and 300 mg SR 47436 (BMS-186295) in mild-to- moderate hypertension.

Sub-Investigator
Double-blind and open-label study of orally administered Dofetilide in patients with an implanted arrhythmia control device.

Sub-Investigator
Evaluation of orally administered Dofetilide in patients with symptomatic Paroxysmal Atrial Fibrillation/Flutter (pAF, pAFL) or Paroxysmal Supraventricular Tachycardia (pSVT).

Sub-Investigator
Effects of BMS 180,291 or placebo on indices of myocardial ischemia in patients with chronic stable angina pectoris undergoing exercise.

Sub-Investigator
Comparison of Intravenous d-Sotalol and placebo in the conversion of atrial fibrillation or flutter to sinus rhythm.

Sub-Investigator
ALLHAT (Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial).

Sub-Investigator
Trial of SR47436 (BMS-186295) for treatment of hypertension.

Sub-Investigator
MK-383 Alone and MK-383 in combination with heparin vs. heparin alone in patients with high risk unstable angina/non-Q-wave myocardial infarction.

Sub-Investigator
VEST Trial: Vesnarinone in heart failure.

Sub-Investigator
EPILOG: Clinical outcome following percutaneous coronary intervention in patients treated with 7e3 Fab Bolus plus 12-hour infusion given with either standard dose weight-adjusted or low-dose weight-adjusted heparin.

Sub-Investigator
MK-383 in patients undergoing PTCA (RESTORE).

Sub-Investigator
Double-blind trial of Azimilide for treatment of atrial fib/flutter and/or PSVT.

Sub-Investigator
Open-label trial to assess long-term safety of Azimilide.

Sub-Investigator
TIMI 10 pilot (TNK-tPA in Acute MI).

Principal Investigator
Telmisartan in mild-to-moderate hypertension.

Sub-Investigator
Xemilofiban Hydrochloride post-stent placement.

Sub-Investigator
PPR Verapamil vs. Procardia XL in treatment of hypertension.

Sub-Investigator
PPR Verapamil vs. Norvasc and Atenolol in patients with chronic stable angina.

Sub-Investigator
RAPPORT: ReoPro in acute myocardial infarction.

Sub-Investigator
Comparison of Mibefradil/Amlodipine in treatment of chronic stable angina.

Sub-Investigator
GUSTO III: Reteplase (r-PA) versus Accelerated Alteplase (t-PA) for treatment of AMI.

Sub-Investigator
Open-label administration of Telmisartan as monotherapy or in combination with other antihypertensive medications.

Sub-Investigator
BMS-200980 in subjects with AMI. (INTIME).

Sub-Investigator
BEST: Beta Blocker Evaluation of Survival Trial.

Sub-Investigator
Trial Comparing Lotrel/Amlodipine for HTN.

Sub-Investigator
Trial Comparing Lotrel/Nifedipine for HTN.

Sub-Investigator
Novastan in patients with heparin-induced thrombocytopenia undergoing PTCA, atherectomy or stent implantation.

Sub-Investigator
PEACE Trial: Prevention of Events with Angiotensin Converting Enzymes Inhibitor Therapy.

Sub-Investigator
Losartan in patients with non-insulin dependent diabetes.

Sub-Investigator
Irbesartan in hypertensive patients with type ii diabetic nephropathy.

Sub-Investigator
Pilot Study: Dosing Regimens of Integrilin vs. Placebo in Patients Undergoing Percutaneous Coronary Intervention.

Sub-Investigator
Dose ranging study of BMS-186716 in mild to mod. Htn (DMPI – NEPACE).

Sub-Investigator
SPICE: Study of Patients Intolerant Of Converting Enzyme Inhibitors.

Sub-Investigator
BR1 vs. Albunex as a contrast enhancing agent for transthoracic echo at rest.

Principal Investigator
CILOSTAZOL VS. PENTOXIFYLLINE or placebo in patients with intermittent claudication secondary to Peripheral Vascular Disease (PVD study).

Sub-Investigator
Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE TRIAL).

Sub-Investigator
Open-label study of Novastan in patients with Heparin-Induced Thrombocytopenia (HIT)/Heparin- Induced Thrombocytopenia and Thrombosis Syndrome (HITTS).

Sub-Investigator
Open-label, long-term study of the antihypertensive activity and safety of BMS-186716, a dual metalloprotease inhibitor, in the treatment of hypertension.

Sub-Investigator
Multi-country, randomized, double-blind, parallel, placebo-controlled trial to assess the effect of Valsartan on morbidity and mortality, signs and symptoms and quality of life in patients with stable chronic congestive heart failure (NYHA Class II-IV).

Sub-Investigator
REOPRO readministration registry – a phase IV observational study.

Sub-Investigator
Genetic Analysis Of Complex Human Traits: Application To Premature Atherosclerotic Heart Disease (GENE QUEST).

Sub-Investigator
A multicenter, double-blind study to assess the efficacy and safety of 50, 100 & 125 mg of Azimilide Dihydrochloride for prophylactic treatment of symptomatic atrial fibrillation / flutter and/or symptomatic paroxysmal superventricular tachycardia.

Sub-Investigator
A multicenter, open label clinical trial to assess the long-term safety of 100 mg of azimilide dihydrocholoride in patients with atrial fibrillation/flutter and/or paroxysmal supraventricular tachycardia.

Sub-Investigator
A phase 1, open-label… to assess the safety, tolerability, and pharmacokinetics of intracoronary administration of RhVEGF in subjects with viable but underperfused myocardium.

Sub-Investigator
Pilot evaluation of the effects of the DMP inhibitor BMS-186716 on functional capacity in subjects with heart failure.

Sub-Investigator
54-week open label assessment of safety & efficacy profile of Atorvastatin as compared to Simvastatin when used to optimally control pts with mixed dyslipidemia.

Principal Investigator
The GUARDIAN trial – Guard during ischemia against necrosis. A double-blind, placebo-controlled, multinational trial to investigate the effect of the Na/H exchange inhibitor HOE 642 (cariporide) on all- cause mortality and myocardial infarction in pts at risk of myocardial necrosis.

Sub-Investigator
Evaluation of safety/tolerability of long-term treatment with DMP-inhibitor BMS-186716 or Lisinopril in subjects with heart failure.

Sub-Investigator
A Phase 3, open label titration study of the chronic efficacy of OPC-18790 for treatment of patients with heart failure.

Sub-Investigator
Randomized, double-blind…AMP 579 in patients with acute myocardial infarction treated with primary angioplasty.

Sub-Investigator
12-week, DB …effect on platelet aggreg. of a dose range of SB 214857 when added to aspirin in patients with MI… APLAUD.

Sub-Investigator
Orbofiban (SC 57099B) (10 & 20 mg twice daily) in pts with stabilized ischemic syndromes.

Sub-Investigator
A Phase 1, open-label, multicenter, dose escalation study to assess safety, tolerability and pharmacokinetics of multiple intravenous administration of rhVEGF in adults with viable but underperfused myocardium.

Sub-Investigator
Double-blind, randomized, multicenter trial of single bolus lanoteplase vs. accelerated alteplase for treatment of subject with AMI (in TIME II).

Co-Investigator
SPEED: Open-label angiographic trial evaluating the benefit of ReoPro plus 12-hr. infusion with and without thrombolytic therapy for AMI.

Sub-Investigator
EXCITE: Xemilofiban administration to patients undergoing coronary angioplasty or stent placement.

Sub-Investigator
ALIVE (Azimilide Post Infarct Survival Evaluation Trial): Determine the effect of 75 or 100 mg of orally administered azimilide vs. placebo on survival in recent MI patients at risk of sudden death.

Sub-Investigator
OPUS (TIMI 16): Trial evaluating the efficacy and safety of Orbofiban in patients with unstable coronary syndromes.

Sub-Investigator
COPERNICUS: Carvedilol prospective randomized cumulative survival trial (The effect of Carvedilol on mortality in patients with severe CHF).

Sub-Investigator
RECREATE Trial: Rescue of closed arteries treated by stent for threatened or abrupt closure.

Sub-Investigator
ORATOR: Oral glycoprotein IIb/IIIa antagonist (RPR 109891) vs. ticlopidine on coronary stent revascularization.

Sub-Investigator
P-selectin feasibility study.

Sub-Investigator
Rapid platelet function analyzer to assess platelet function during coronary interventions.

Sub-Investigator
Management of acute coronary syndrome with p-selectin profile (MAPS1).

Sub-Investigator
TIMI 15B. Trial to assess safety and efficacy of IV Klerval administration 24 to 96 hrs, followed by oral Klerval administration for 4 weeks in pts with acute coronary syndromes.

Sub-Investigator
Study to assess the equivalence of the accumetrics Rapid Platelet Function Assay (RPFA) in pts who are undergoing coronary intervention procedures to platelet aggregometry using a Chrono-Log aggregometer for detection of platelet aggregation.

Sub-Investigator
Phase II, randomized, double-blind, multi-center, acetylsalicylic acid-controlled, multidose study of DMP 754 in pts with coronary artery disease.

Sub-Investigator
RPFA II: Using a Chrono-Log aggregometer for detection of platelet aggregation.

Principal Investigator
Study of time course, magnitude and consistency of platelet inhibition by Abciximab, Aggrastat or Eptifibatide in patients with unstable angina pectoris undergoing PTCA.

Sub-Investigator
ASTRA Trial: Platelet Aggregation Response of IV AR-C69931MX in patients undergoing PTCA, with or without stent.

Sub-Investigator
NICE-4 Trial: Safety of Enoxaparin therapy in patients undergoing PTCA receiving concomitant Abciximab therapy.

Sub-Investigator
REVIVE Trial: DUET Stent for saphenous vein grafts.

Sub-Investigator
Study evaluating platelet function with Accumetrics Ultegra-Rapid Platelet Function Assay (RPFA) in patients undergoing coronary interventions using Platelet Glycoprotein IIb/IIIa inhibitors (RPFA-4 study).

Sub-Investigator
SAFER Study: Saphenous Vein Graft Angioplasty Free of Emboli Randomized Study.

Sub-Investigator
DMP 754 (Roxifiban) in combination with aspirin in patient with CAD.

Sub-Investigator
VALIANT Trial: Valsartan in AMI.

Sub-Investigator
BRAVO: Blockade of the GP IIb/IIIa receptor to avoid vascular occlusion (Lotrafiban or placebo).

Sub-Investigator
PRESTO: Prevention of restenosis with Tranilast in its outcomes.

Sub-Investigator
ENABLE-2: Endothelin Antagonist Bosentan in lowering cardiac events in heart failure

Sub-Investigator
Recombinant Fibroblast Growth Factor: 2 (rFGF-2) in patients with CAD.

Sub-Investigator
Dalteparin/Abciximab in combination during PCI for acute coronary syndrome (Fragmin). ]

Sub-Investigator
OVERTURE: Omapatrilat vs. Enalapril randomized trial of utility of reducing events.

Sub-Investigator
Ultegra reference range study.

Sub-Investigator
Extension trial to evaluate one-year safety in pts. with CAD who have been treated with intracoronary rFGF-2 or placebo in Chiron Protocol CS-FGF002.

Sub-Investigator
Evaluate the effects of twice daily Celecoxib vs. placebo on blood pressure in HTN patients whose blood pressure is controlled with the ACE inhibitor, Lisinopril.

Sub-Investigator
Health Alliance Protocol for pharmacologic reperfusion of AMI: evaluation of the benefit of ReoPro bolus plus 12-hour infusion with reduced dose thrombolytic therapy for AMI.

Sub-Investigator
A blinded, randomized comparative trial of Dalteparin vs. unfractionated heparin in conjunction with Abciximab Platelet GP IIb/IIIa inhibition during and following elective PCI.

Sub-Investigator
A study to evaluate blood samples obtained from pts. for development of platelet function assay (Accumetrics).

Sub-Investigator
Ultegra Reference Range Protocol: (Accumetrics).

Sub-Investigator
DISTINCT abrupt closure or threatened abrupt closure registry.

Sub-Investigator
THRIVE V: Double-blind, efficacy & safety study of the oral direct thrombin inhibit, H 376/96 vs. standard therapy in pts. with acute DVT with or without PE.

Sub-Investigator
A double-blind … study to compare the safety & efficacy of Diltiazem HCL extended release capsules to placebo dose at bedtime & to G99 dosed in the AM in pts. with essential HTN.

Sub-Investigator
PROVE IT: Pravastatin or Atorvastatin evaluation and infection therapy.

Sub-Investigator
A long-term, O/L Study of CS-866 & Hydrochlorothiazide in patients with Essential HTN.

Sub-Investigator
OCTAVE: Omapatrilat cardiovascular treatment assessment vs. Enalapril .

Sub-Investigator
PYRAMID: A parallel-dose randomized,…. …study of YM337 in Pts. undergoing PCI to provide pharmacokinetic, pharmacodynamic & safety data.

Sub-Investigator
REPLACE: Randomized evaluation in PCI linking Angiomax to reduced clinical events.

Sub-Investigator
Field trial evaluation of the Rapidpoint coag & low molecular weight heparin card.

Sub-Investigator
SAGE: Study assessing goals in the elderly. …study comparing the effects of aggressive lipid lowering with moderate lipid lowering on the reduction of the total duration of myocardial ischemia ….measured by Holter monitoring by comparing the maximal doses of two statins.

Sub-Investigator
Double-blind, randomized, ……..study of Ranolazine SR 750 mg twice a day administered alone & in combination with Digoxin 0.125 mg once a day in pts. with CHF.

Sub-Investigator
AVALON: evaluation of the safety & efficacy of dual therapy with Atorvastatin plus Amlodipine when compared to either therapy alone in the tx. of pts. with simultaneous hyperlipidemia:

Sub-Investigator
Beraprost in patients with intermittent claudication: a continuation study.

Sub-Investigator
8 week randomized double-blind….evaluate the effects of ZD4522 40 mg on myocardial ischemia in subjects with CAD (protocol 4522IL/0043).

Sub-Investigator
TELLAR: 6-week, dose-comparison study ….efficacy of Rosuvastatin vs. Atorvastatin, Cerivastatin, Pravastatin & Simvastatin in subjects with hypercholesterolemia (protocol 4522IL/0065).

Sub-Investigator
Effect of Oral NO-1886 on lipoproteins in subjects with Type II Diabetes Group Mellitus who are receiving statin therapy (TAP NO-18886-01-017).

Principal Investigator
EXPEDITION Trial: …IV Treatment …HOE642 on all-cause mortality & non-fatal MI in Pts. at risk of myocardial necrosis during and after CABG surgery.

Sub-Investigator
AQUAVIT: Aquaretic Vasopressin V2 Receptor InhibitorTrial.

Sub-Investigator
SYNERGY: A prospective, randomized, open-label multicenter study in pts. presenting with Acute Coronary Syndromes (ACS).

Sub-Investigator
PRE-CHILL Study: cryoplasty hyperplasia inhibition prevents late loss feasibility.

Sub-Investigator
Accumetrics (P95053): Evaluation of baseline (uninhibited ) reference range for the Ultegra System in subj. receiving tx. for CAD.

Sub-Investigator
A randomized, ….study to compare the blood pressure response of pts. with group moderate HTN receiving Lercanidipine or placebo.

Sub-Investigator
Study of the effects of Zoniporide on perioperative cardiac events in high risk subjects undergoing noncardiac vascular surgery.

Sub-Investigator
CREST: Cilostazol for Restenosis Trial.

Sub-Investigator
PREVAIL: Study to evaluate the safety & efficacy of BO-653 in the prevention of post-angioplasty restenosis in stented lesions.

Sub-Investigator
REPLACE-2: A randomized evaluation in PCI lining Angiomax to reduced clinical events.

Sub-Investigator
A Phase IIIb, multicenter…..the safety, efficacy & tolerability of Fenoldopam Mesylate in subjects undergoing invasive cardiology procedures:

Sub-Investigator
REVIVE: Randomized evaluation of IV Levosimendan efficacy vs. placebo in the short term tx. of decompensated chronic heart failure.

Sub-Investigator
TRANSCEND: Telmisartan randomized assessment study in ACE-inhibitor intolerant subjects with cardiovascular disease.

Sub-Investigator
ELECT study: Evaluating Enox Clotting Times. Multicenter evaluation of the Rapidpoint ENOX monitoring system among PCI patients receiving enoxaparin.

Sub-Investigator
A randomized, double-blind, multicenter, positive controlled, parallel-group study to evaluate the
& efficacy of Amlodipine and Benazepril administered in combination compared to Benazepril alone in hypertensive patients not adequately controlled with Benazepril alone.

Sub-Investigator
SOLACE: A multicenter, randomized, double-blind, parallel group study comparing the efficacy of Lotrel versus Amlodipine in the treatment of moderate to severe hypertension– Principal Investigator

Sub-Investigator
A randomized, double-blind, multicenter, multifactorial, placebo-controlled, parallel group study to evaluate the efficacy and safety of Valsartan and amlodipine combined and alone in hypertensive patients.

Sub-Investigator
A Phase II, randomized….pilot study of ETC-588 in patients with acute coronary syndromes.

Sub-Investigator
Evaluation of the thrombolytic assessment (TAS) & thrombin inhibitor management (TIM-2) testcard.

Sub-Investigator
ACT (guided Dalteparin in percutaneous coronary intervention (ACT: ONE).

Sub-Investigator
SWITCH: Switching from Lovenox (enoxaparin) to Angiomax in pts. with acute coronary syndromes without ST-segment elevation undergoing PCI.

Sub-Investigator
TIMI-38, A Comparison of CS-747 and Clopidogrel in acute coronary syndrome subjects who are to undergo percutaneous coronary intervention.

Sub-Investigator

TENACITY: A randomized, multicenter, double-blind, Abciximab-controlled study to evaluate the efficacy of Tirofiban versus Abciximab among subjects undergoing percutaneous coronary intervention with stent placement receiving Bivalirudin or Heparin.

Sub-Investigator
Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT) An imaging study in patients with unstable atherosclerotic lesions.

Sub-Investigator
IMPROVE IT: IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE IT).

Sub-Investigator
SWAP: SWitching Anti-Platelet Study: A pharmacodynamic comparison of Prasugrel (LY640315) versus Clopidogrel in subjects with acute coronary syndrome who have recently undergone percutaneous coronary intervention and are receiving Clopidogrel.

Sub-Investigator
CHAMPION: A clinical trial comparing Cangrelor to Clopidogrel in subjects who require PCI.

Sub-Investigator
Collection of carotid plaque for methods adaptation and optimization.

Sub-Investigator
INNOVATE-PCI: A randomized, double-blind, active-controlled trial to evaluate intravenous and oral PRT060128, a selective and reversible P2Y12-Receptor Inhibitor, vs. Clopidogrel, as a novel antiplatelet therapy in patients undergoing non-urgent percutaneous coronary interventions.

Sub-Investigator
Protocol:A01-03:Double-Blind,randomized,placebo-controlled,12-weekstudy ofthe safety and efficacy of ATHX-105 Phosphate for the treatment of obesity.

Sub-Investigator
A randomized, double-blind, outpatient, crossover study of the anti-platelet effects of AZD6140 compared with Clopidogrel in patients with stable coronary artery disease previously identified as Clopidogrel Non- responders or Responders (RESPOND).

Sub-Investigator
A randomized, double-blind, outpatient, crossover study of the anti-platelet Effects of AZD6140 compared with Clopidogrel in patients with stable coronary artery disease previously identified as Clopidogrel Non- responders or Responders (RESPOND).

Principal Investigator
Injection of Autologous CD34-positive cells for improved symptomatic relief and ischemic wound healing in subjects with moderate or high-risk critical limb ischemia.

Sub-Investigator
A Phase II, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of PROCHYMAL® (ex vivo cultured adult human mesenchymal stem cells) intravenous infusion following acute myocardial infarction.

Sub-Investigator
INFUSE-AMI: A 2×2 factorial, randomized, multicenter, single-blind evaluation of intracoronary Abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior st-segment elevation myocardial infarction.

Sub-Investigator
DAPT: A prospective, multi-center, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of Dual Antiplatelet Therapy (DAPT) in subjects undergoing percutaneous coronary intervention (PCI) with either drug-eluting stent (DES) or bare metal stent (BMS) placement for the treatment of coronary artery lesions..

Sub-Investigator
SOLID / TIMI-52: A clinical outcomes study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).

Sub-Investigator
Cardiovascular outcomes study to evaluate the potential of Aleglitazar to reduce cardiovascular risk in pts with a recent ACS event and type 2 diabetes mellitus (Alecardio).

Sub-Investigator
RIVAROX-ACS-3001/ATLAS II TIMI 51: A randomized, double-blind, placebo-controlled, event- driven multicenter study to evaluate the efficacy and safety of Rivaroxaban in subjects with acute coronary syndrome.

Sub-Investigator
ELEVATE / TIMI 56: Escalating cLopidogrEl by inVolving A geneTic stratEgy –Thrombolysis In Myocardial Infarction 56.

Sub-Investigator
A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous Canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP (#CACZ885M2301).

Sub-Investigator
BOSS: Evaluation of Sodium Bicarbonate to Reduce Contrast-Induced Chronic Kidney Injury in Subjects with Advanced Chronic Kidney Disease (CKD) Who are Undergoing Angiography.

PRESENTATIONS

Bard Lead Cath Lab Tech Workshop, Phoenix, AZ, September 10, 2010.
Invited Lecturer
Crossing SFA CTOs with the Crosser

Complex Cardiovascular Catheter Therapeutics, Advanced Endovascular and Coronary Intervention Global Summit, Baltimore, MD, June 20-24, 2010.
Invited Lecturer
Plaque Excision Atherectomy in Complex Femoralpopliteal Disease Including CTO: Tips, Tricks and Supportive Data

New Cardiovascular Horizons, June 2-5, 2010.
Operator
Live Cases from The Christ Hospital, Cincinnati, OH

LEAD, Grand Rapids, MI, May 21-22, 2010.
Invited Lecturer
CTOS: Crosser as First Line Therapy

Innovations and Practical Applications in Vascular Surgery: Special Sessions: Management of Non- Healing Wounds, Columbia University, New York, NY, May 13-14, 2010.
Invited Lecturer
Atherectomy: Comparison of CSI, Pathway and EV3
Treatment of Renal and Mesenteric Artery Occlusive Disease: Are the Days of Open Surgery Over?

China Interventional Therapeutics (CIT), Beijing, China, March 30-April 3, 2010.
Invited Lecturer
Plaque Excision as First Line Therapy.

Adams County Hospital, March 15, 2010.
Grand Rounds
ABCs of Peripheral Vascular Disease

The Christ Hospital, Cincinnati, OH, March 5, 2010.
Grand Rounds
ABCs of Peripheral Vascular Disease

Peripheral Vascular Symposium 2009: A Multi-Specialty Look at a Multifaceted Disease, October 3, 2009.
Founder, Invited Lecturer
Screening for Peripheral Vascular Disease
Crossing and Treating Occluded Iliacs, New Cardiovascular Horizons, July 9-11, 2009.

Capital Cardiovascular Conference, Advanced Endovascular and Coronary Intervention Global Summit, Baltimore, MD, June 14-17 2009.
Operator, Invited Lecturer
Live Case Transmission: Complex BTK Disease
SFA Stenting: Are High Radial Strength and Helical Design the Answers?

Ohio State Podiatry Society, Columbus, OH, June 12, 2009.
Invited Lecturer
Critical Limb Ischemia

The Christ Hospital, Cincinnati, OH, April 12, 2009.
Medical Grand Rounds
Peripheral Vascular Disease for the Primary Care Physician

Leipzig Interventional Course, The European Board for Accreditation in Cardiology, Leipzig, Germany, January 14-17 2009.
Invited Lecturer, Moderator
Patient-specific Solutions for Calcified Lesions Treatment of Calcified Lesions: New Technology Challenges in Peripheral Arterial Interventions

Debates & Controversies in Treatment of Lower Extremity Arterial Disease Conference, Lake Tahoe, CA, December 11-14, 2008.
Debater
EPD Devices: Only with High-Risk Anatomy
Recanalizing the SFA/POP CTO: Wire Technique is All You Need

Below the Knee (BTK): New Advances in Critical Limb Ischemia, , Phoenix, AZ, October 2-4, 2008.
Course Director, Operator, Invited Lecturer
Aortoiliac Disease Management Tips, Tricks and Tools Live Case: SFA CTO
CTOs in the CLI: The Rule Not the Exception – Center Luminal Crossing as “First Line Therapy” to Improve Outcomes,
New Cardiovascular Horizons, September 10-13-2008.

Endovascular Treatment of Superficial Artery Disease, 8th Annual Treatment of Cardiovascular Disease; Present Strategies & Future Solutions, Las Vegas, NE, July 14, 2008.

Below the Knee (BTK): New Advances in Critical Limb Ischemia, Orlando, FL, April 24-26, 2008.
Course Director, Operator, Lecturer
Lessons Learned and Equipment Needs: Infrapopliteal Complications How to Build a Vascular Practice
Screening: Importance of Early Detection and Aggressive Detection CTOs in the SFA: Cases, Tools & Techniques
Live Case: SFA CTO

Endovascular Treatment of Superficial Femoral Artery Disease, 8th Annual Endovascular Treatment of Cardiovascular Disease Conference, Hollywood Presbyterian Medical Center, Los Angeles, CA, October 4, 2008.

Endovascular Treatment of Superficial Femoral Artery Disease, New Cardiovascular Horizons, September 10-13, 2008.

Sales Acquisition Seminar, Transcatheter Cardiovascular Therapeutics, March 31-April 1, 2008.
Invited Lecturer
Disease State Overview: Algorithm Preferences and Treatment Approaches Conservative to Aggressive: Treatment Approaches and Customer Segments

Sales Acquisition Seminar, Transcatheter Cardiovascular Therapeutics, October 15, 2007.
Invited Lecturer
Disease State Overview: Algorithm Preferences and Treatment Approaches Conservative to Aggressive: Treatment Approaches and Customer Segments

Below the Knee (BTK): New Advances in Critical Limb Ischemia, Chicago, IL, September 13-15, 2007.
Course Director, Operator, Lecturer, Faculty Panelist
Lessons Learned and Equipment Needs: Infrapopliteal Complications
Fellows Training Session: Crossing CTOs

Live SilverHawk Case Demonstration

CTOs: The Rule, Not the Exception in CLI, New Cardiovascular Horizons, New Orleans, LA, November 1-4, 2006.

Below the Knee (BTK): New Advances in Critical Limb Ischemia, Atlanta, GA, September 14-16, 2006.
Course Director, Operator, Lecturer
CTOs in the SFA: Cases, Tools & Techniques
Treating Calcified Lesions
Equipment Needs for Infrapopliteal Complications
Live Case SFA CTO

Below the Knee (BTK): New Advances in Critical Limb Ischemia, Philadelphia, PA, April 27-29, 2006.

Course Director, Lecturer, Faculty Panelist, Operator-Live Case Demonstration

Complex Cases: From the Common Femoral to Dorsalis Pedis
Lessons Learned: Infrapopliteal Complications

Handling Complex Infrapopliteal Complications
Post-Intervention Management & Surveillance
Live CTO Demonstration

Live Case Demonstration: Plaque Excision from Superficial Femoral & Tibial-Peroneal Trunk
Arteries Using the Silverhawk Device

Below the Knee (BTK): New Advances in Critical Limb Ischemia, Dallas, TX, January 26-28, 2006.
Course Director, Operator, Lecturer
New Crossing Techniques & Tools for CTOs Lessons Learned: Infrapopliteal Complications Live Case: SFA CTO

Below the Knee (BTK): New Advances in Critical Limb Ischemia, Dallas, TX, November 12-15, 2005.
Course Director, Lecturer
New Crossing Techniques for CTOs L
Live Case: SFA CTO

Below the Knee (BTK): New Advances in Critical Limb Ischemia, Atlanta, GA, September 15-17, 2005.
Course Director, Operator, Lecturer, Faculty Panelist
New Crossing Techniques for CTOs
Lessons Learned: Infrapopliteal Complications
Post-Intervention Management & Surveillance Live Case: SFA CTO

Below the Knee (BTK): New Advances in Critical Limb Ischemia, Chicago, IL, May 19-21, 2005.
Course Director, Operator, Lecturer, Faculty Panelist
Post-Procedure Management & Surveillance
Complex Case Session: Calcification
Treating Calcified Lesions
Live Case from The Christ Hospital, Cincinnati, OH: SFA CTO

SilverHawk Plaque Excision: Early Experience in Infrapopliteal Disease and Limb Salvage, Vascular Interventional Advances (VIVA), Mandalay Bay, NE, October 19, 2000.

Second Annual Primer on Peripheral Arterial Disease: An Interventional Course for Advanced Angioplasty Fellows, Cincinnati, OH, September 12-13, 2000.

First Annual Primer on Peripheral Arterial Disease: An Interventional Course for Advanced Angioplasty Fellows, Cincinnati, OH, September 8-11, 1999.

Acute Coronary Syndrome, University of Cincinnati, Cincinnati, OH, May 1999.
Cardiology Grand Rounds

Adjunctive Therapy in the Treatment of Acute MI, Clinton Memorial Hospital Medical Staff, April 1999.

A Multidisciplinary Approach to Cardiovascular and Metabolic Risk Management, Bristol-Myers Squibb,
Aventura, FL, April 1999.

Peripheral Vascular Disease, Franciscan Hospital Residents Program, January 1999.

New Vistas in Acute-Care Cardiovascular Therapies Research Program – COR Therapeutics, Inc., September 1998.

Peripheral Vascular and Arterial Venous Disease, University of Cincinnati, August 1998.
Cardiology Grand Rounds

Management of CHF Post-MI, Hoechst Marion Roussel Cardiovascular National Visiting Professors Program, August 1998.

Peripheral Vascular Disease, Adams County Hospital Medical Staff, August 1998.

Peripheral Vascular Disease: The Other Side, University of Cincinnati, Cincinnati, OH, June 1998.
Cardiology Grand Rounds

Treatment of Diabetic Hypertension, June 1998.

Updates on Clinical Interventional Trials, University of Cincinnati, Cincinnati, OH, May 1997.
Cardiology Grand Rounds

Acute Myocardial Infarction, Clinton Memorial Hospital, October 1996.

Update in the Treatment of Acute Myocardial Infarction, University of Cincinnati, Cincinnati, OH, April 1996.
Cardiology Grand Rounds

Updates in the Development of Glycoprotein II/Ilia Inhibitors, University of Cincinnati, Cincinnati, OH, April 1996.
Cardiology Grand Rounds

Success, Failure and the Future Promise of Coronary Artery Intervention, University of Cincinnati, Cincinnati, OH, March 1996.
Cardiology Grand Rounds

Stent Atherectomy, Emergency Medicine Grand Rounds, University of Cincinnati, Cincinnati, OH, February 1996.
Cardiology Grand Rounds

Cardiac Pre-Operative Clearance for the Vascular Patient, University of Cincinnati, Cincinnati, OH, October 15, 1995.
Vascular Surgery Grand Rounds

Calcium: How it Affects the Heart, Cardiology Grand Rounds, University of Cincinnati, Cincinnati, OH, December 15, 1994.
Cardiology Grand Rounds

Cardiac Trauma, Cardiology Grand Rounds, University of Cincinnati, Cincinnati, OH, December 12, 1993.
Cardiology Grand Rounds

Myocardial Tumors, Cardiology Grand Rounds, University of Cincinnati, Cincinnati, OH, December 14, 1992.
Cardiology Grand Rounds

Peripheral Vascular Disease for the Cardiologist, University of Cincinnati, Cincinnati, OH, December 15, 1991.
Cardiology Grand Rounds

Carotid Artery Disease, Carotid Artery Disease, University of Cincinnati, Cincinnati, OH, March 16 1990.
Cardiology Grand Rounds